Literature DB >> 27397044

Combined modality adjuvant therapy for high-risk endometrial cancer.

Adriaan Vanderstichele1, Patrick Neven2, Ignace Vergote1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27397044     DOI： 10.1016/S1470-2045(16)30152-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Nomegestrol Acetate Suppresses Human Endometrial Cancer RL95-2 Cells Proliferation In Vitro and In Vivo Possibly Related to Upregulating Expression of SUFU and Wnt7a.

Authors:  A-Ying Ma; Shu-Wu Xie; Jie-Yun Zhou; Yan Zhu
Journal:  Int J Mol Sci       Date:  2017-06-22       Impact factor: 5.923

2.  Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.

Authors:  Weiwei Feng; Nan Jia; Haining Jiao; Jun Chen; Yan Chen; Yueru Zhang; Menghan Zhu; Chongying Zhu; Lifei Shen; Wenqing Long
Journal:  J Transl Med       Date:  2021-02-03       Impact factor: 5.531

3.  Endometrial cancer: mapping the global landscape of research.

Authors:  Dörthe Brüggmann; Katja Ouassou; Doris Klingelhöfer; Michael K Bohlmann; Jenny Jaque; David A Groneberg
Journal:  J Transl Med       Date:  2020-10-12       Impact factor: 5.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.